Methenamine

Methenamine

SCHEMBL6698092

C1N2CN3CN1CN(C2)C3.O=[N+]([O-])[O-].[Ni]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GAA P10253 1/20 0.40
CA5A P35218 1/20 0.31
CA5B Q9Y2D0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methenamine SCHEMBL4447637 0.92 MEN1 (0.43) MEN1KMT2AGAACA5ACA5B
Methenamine SCHEMBL10433207 0.92 MEN1 (0.43) MEN1KMT2AGAACA5ACA5B
Methenamine SCHEMBL3047629 0.92 MEN1 (0.43) MEN1KMT2AGAACA5ACA5B
Methenamine SCHEMBL3639801 0.81 CA5A (0.57) MEN1KMT2AGAACA5ACA5B
Methenamine SCHEMBL5573914 0.81 CA5A (0.57) MEN1KMT2AGAACA5ACA5B
SCHEMBL1705590 0.76 GAA (0.36) GAA
SCHEMBL1121202 0.73
SCHEMBL8999403 0.73 MEN1 (0.75) MEN1KMT2ACA5ACA5B
Water SCHEMBL11146310 0.69
Water SCHEMBL987709 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102654-A1 Process facilitating the regeneration of a catalyst based on a zeolite used in an acylation reaction, catalyst and use SPAGNOL MICHEL (FR) 2004-05-27 US disclosed
US-20020120169-A1 Process facilitating the regeneration of a catalyst based on a zeolite used in an acylation reaction, catalyst and use SPAGNOL MICHEL (FR) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120169-A1 Process facilitating the regeneration of a catalyst based on a zeolite used in an acylation reaction, catalyst and use AFF4, APEH, TECR MEN1 2293/4885KMT2A 116/4885GAA 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.